Breast Cancer
📧 Sign up to get email alerts when something new happens for Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-07-15Clinical Trial Update: Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml® [NA]
A Phase IV trial update for breast brachytherapy using Mammosite-Ml in breast cancer and ductal carcinoma in situ has completed with results…
-
CLINICAL_TRIALS trial_result · 2021-07-09Clinical Trial Update: NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer [Phase 2]
Phase 2 trial evaluating everolimus plus cisplatin in triple-negative breast cancer has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-07-09Clinical Trial Update: Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer [Phase 2, Phase 3]
Clinical trial update for apatinib in neoadjuvant therapy for breast cancer (Phase 2/Phase 3).
-
CLINICAL_TRIALS trial_result · 2021-07-09Clinical Trial Update: Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer [Phase 3]
Phase 3 trial evaluating exemestane with or without entinostat in Chinese patients with hormone receptor-positive, locally advanced or metas…
-
CLINICAL_TRIALS trial_result · 2021-07-02Clinical Trial Update: Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer [Phase 2]
Phase 2 clinical trial update evaluating inetetamab with metronomic cyclophosphamide and an aromatase inhibitor in metastatic HER2-positive,…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-07-01Clinical Trial Update: A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer [Phase 1, Phase 2]
Phase 1/2 trial evaluating palbociclib in combination with bazedoxifene for hormone receptor–positive breast cancer has completed with resul…
-
FDA approval · 2021-07-01FDA Approved: DOCETAXEL — Original Application (Gland Pharma Limited)
FDA approves Gland Pharma Limited's generic docetaxel as an Original Application, adding a new generic option for cancer chemotherapy.
-
CLINICAL_TRIALS trial_result · 2021-06-30Clinical Trial Update: Pembrolizumab and Paclitaxel in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2') [Phase 2]
Phase 2 trial investigating pembrolizumab with paclitaxel for hormone receptor-positive, hypermutated metastatic breast cancer identified by…
-
FDA approval · 2021-06-28FDA Approved: NERLYNX — Supplemental Application (Puma Biotechnology, Inc.)
FDA approves a supplemental application for Nerlynx (neratinib) from Puma Biotechnology, Inc.
-
CLINICAL_TRIALS trial_result · 2021-06-23Clinical Trial Update: Hypofractionated Radiation Therapy in Patients With Breast Cancer [Phase 3]
Phase 3 trial evaluating hypofractionated radiation therapy in breast cancer has completed.
-
CLINICAL_TRIALS trial_result · 2021-06-23Clinical Trial Update: Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation [Phase 2]
Phase 2 trial updating the combination of fulvestrant and anlotinib in HR+/HER2- metastatic breast cancer with FGFR mutation.
-
FDA approval · 2021-06-22FDA Approved: LETROZOLE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for Letrozole submitted by Teva Pharmaceuticals USA, Inc. The approval concerns the generic drug…
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer [Phase 1, Phase 2]
A phase 1/2 study of GDC-0810 as a single agent or in combination with palbociclib and/or an LHRH agonist in women with locally advanced or …
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer [Phase 1, Phase 2]
Clinical trial update evaluating safety and efficacy of estetrol in postmenopausal women with advanced estrogen receptor-positive breast can…
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy? [NA]
Completed clinical trial evaluating HER2-targeted PET/CT imaging to identify unsuspected HER2-positive breast cancer metastases that may be …
-
FDA label_change · 2021-06-17FDA Approved: ZOLADEX — Supplemental Application (TerSera Therapeutics LLC)
FDA supplemental application for ZOLADEX (goserelin) submitted by TerSera Therapeutics LLC, likely related to labeling changes for the produ…
-
CLINICAL_TRIALS trial_result · 2021-06-16Clinical Trial Update: Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC [Phase 3]
Phase 3 trial comparing ribociclib-endocrine therapy versus chemotherapy as first-line treatment in visceral metastatic breast cancer was te…
-
CLINICAL_TRIALS trial_result · 2021-06-15Clinical Trial Update: Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer [Phase 4]
Phase 4 trial comparing the immunogenicity of Peg-filgrastim versus Neulasta as an adjunct to chemotherapy in breast cancer; results have be…
-
CLINICAL_TRIALS trial_result · 2021-06-14Clinical Trial Update: Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast Cancer [Phase 1]
Phase 1 study evaluating DS-8201a (trastuzumab deruxtecan) effect on QT/QTc interval and pharmacokinetics in HER2-expressing breast cancer h…
-
CLINICAL_TRIALS trial_result · 2021-06-11Clinical Trial Update: Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery [Phase 2]
Phase 2 trial update for AVB-620 in women with primary breast cancer undergoing surgery has completed.
-
CLINICAL_TRIALS trial_result · 2021-06-09Clinical Trial Update: Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer [Phase 2]
Phase 2 trial evaluating the efficacy of anastrozole and fulvestrant in ER-positive, HER2-negative operable breast cancer.
-
CLINICAL_TRIALS trial_result · 2021-06-08Clinical Trial Update: A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature [Phase 2]
A Phase 2 trial evaluating the efficacy of rucaparib in metastatic breast cancer with a BRCAness genomic signature has completed.
-
CLINICAL_TRIALS trial_result · 2021-06-07Clinical Trial Update: Pilot Clinical Study on a Low-power Electromagnetic Wave Breast Imaging Device for Cancer Screening Purposes. [NA]
Pilot study of a low-power electromagnetic wave breast imaging device for cancer screening has completed; results posted in 2021.
-
CLINICAL_TRIALS trial_result · 2021-06-04Clinical Trial Update: Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer [Phase 2]
Phase 2 trial update on pyrotinib as a neoadjuvant treatment for HER2-positive early breast cancer with non-objective response.
-
CLINICAL_TRIALS trial_result · 2021-06-03Clinical Trial Update: A Study of SHR6390 in Combination With Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer [Phase 3]
A Phase 3 clinical trial evaluating SHR6390 in combination with Fulvestrant for HR-positive, HER2-negative advanced breast cancer.